Traws Pharma Targets Hantavirus With New Antiviral Program for 30–50% Fatality Disease
Traws Pharma is initiating clinical development of small molecule antiviral candidates targeting Hantavirus, a rodent-borne virus with a 30–50% human fatality rate. The company will leverage its existing negative-strand RNA antiviral platform and proprietary libraries to identify and advance lead compounds for Hantaan virus treatment and stockpiling.
1. Hantavirus Program Initiation
Traws Pharma is initiating development of small molecule antiviral candidates specifically targeting Hantavirus infections, including Hantaan virus, leveraging its clinical and non-clinical drug assets. The program aims to rapidly identify lead compounds capable of inhibiting negative-strand RNA virus replication and advance them into clinical evaluation.
2. Fatality Rate and Unmet Need
Hantavirus infections have a human fatality rate of 30–50% with no approved treatments, underscoring urgent medical and national security needs. Recent outbreaks in multiple regions highlight the importance of emergency therapeutic development and potential stockpiling to mitigate future crises.
3. Antiviral Platform and Candidate Selection
The company’s platform focuses on negative-strand RNA viruses, using evolved viral protein targets absent in humans to ensure high specificity and safety. Proprietary chemical libraries and existing viral testing networks will support rapid screening and optimization of clinical candidates.
4. Next Steps and Development Plans
Traws plans to leverage its established drug development network to file IND applications and initiate Phase 1 studies, with options for monotherapy or combination regimens to maximize potency. The company anticipates progressing lead candidates into clinical trials and securing partnerships for manufacturing and stockpiling.